A new impedimetric biosensor utilizing VEGF receptor-1 (Flt-1): early diagnosis of vascular endothelial growth factor in breast cancer.

A new impedimetric biosensor, based on the use of vascular endothelial growth factor receptor-1 (VEGF-R1), was developed for the determination of vascular endothelial growth factor (VEGF). VEGF-R1 was immobilized through covalent coupling with 3-mercaptopropionic acid which formed a self-assembled monolayer on gold electrodes. Cyclic voltammetry (CV) and electrochemical impedance spectroscopy techniques were employed to characterize the immobilization process and to detect VEGF. To successfully construct the biosensor current, experimental parameters were optimized. Kramers-Kronig Transform was performed on the experimental impedance data. The obtained results provided a linear response range from 10 to 70 pg/mL human VEGF. The applicability of the developed biosensor in the determination of VEGF in a spiked artificial human serum sample was experienced, yielding average recovery of 101%, in that order, with an average relative deviation value less than 5%.

[1]  Bingwen Wang,et al.  A review of AC impedance modeling and validation in SOFC diagnosis , 2007 .

[2]  Jeffrey R. Whiteaker,et al.  The evolving role of mass spectrometry in cancer biomarker discovery , 2009, Cancer biology & therapy.

[3]  R. Pei,et al.  Amplification of antigen-antibody interactions based on biotin labeled protein-streptavidin network complex using impedance spectroscopy. , 2001, Biosensors & bioelectronics.

[4]  P. Boffetta.  Exploring a cancer biomarker: the example of C-reactive protein. , 2010, Journal of the National Cancer Institute.

[5]  D. Charnock-Jones,et al.  Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. , 1999, Molecular endocrinology.

[6]  G. D'Amico,et al.  Biopathological significance of single cell DNA aneuploidy measured by static cytometry in breast cancer. , 2001, Breast.

[7]  J. Bergh,et al.  Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Diamandis,et al.  Tissue culture‐based breast cancer biomarker discovery platform , 2008, International journal of cancer.

[10]  V. Levenson,et al.  Biomarkers for early detection of breast cancer: what, when, and where? , 2007, Biochimica et biophysica acta.

[11]  Moon-Ho Jo,et al.  Electrical detection of VEGFs for cancer diagnoses using anti-vascular endotherial growth factor aptamer-modified Si nanowire FETs. , 2009, Biosensors & bioelectronics.

[12]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  W. Yiming,et al.  Studies on Self‐Assembly Monolayers of Cysteine on Gold by XPS, QCM, and Electrochemical Techniques , 2001 .

[14]  R. Kronig.  On the Theory of Dispersion of X-Rays , 1926 .

[15]  Robert Gray,et al.  High DNA content and prognosis in lymph node positive breast cancer. A case control study by the university of Leiden and ECOG , 2004, Breast Cancer Research and Treatment.

[16]  Chen-zhong Li,et al.  Amperometric micro-immunosensor for the detection of tumor biomarker. , 2009, Biosensors & bioelectronics.

[17]  G. Laguens,et al.  Biomarkers in breast cancer , 2006 .

[18]  Hsien-Chang Chang,et al.  Electrochemical evaluation of avidin-biotin interaction on self-assembled gold electrodes , 2005 .

[19]  G. Conn,et al.  Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Bernard A. Boukamp,et al.  A Linear Kronig‐Kramers Transform Test for Immittance Data Validation , 1995 .

[21]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[22]  I. Willner,et al.  Probing Biomolecular Interactions at Conductive and Semiconductive Surfaces by Impedance Spectroscopy: Routes to Impedimetric Immunosensors, DNA‐Sensors, and Enzyme Biosensors , 2003 .

[23]  R Bicknell,et al.  Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. , 2000, Cancer research.

[24]  H. Rochefort,et al.  Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[25]  D. Macdonald,et al.  Electrochemical Impedance Spectroscopy , 2012 .

[26]  G. Hortobagyi,et al.  Critical evaluation of prognostic factors. , 1996, Seminars in oncology.

[27]  P. Devilee,et al.  Genetic susceptibility for breast cancer: how many more genes to be found? , 2007, Critical reviews in oncology/hematology.

[28]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[29]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  I. Ellis,et al.  Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer , 2005, Advances in anatomic pathology.

[31]  R. González-Cámpora,et al.  Apoptosis in breast carcinoma. , 2000, Pathology, research and practice.